PMC8373729

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV on ART in Botswana were not at increased risk for gestational diabetes compared to pregnant women without HIV, after adjusting for age, education, BMI, and gravidity.

Effect: null; aOR=0.83; CI: 95% CI=0.37, 1.85

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97

Pregnant women living with HIV receiving dolutegravir-based ART had a 66% lower risk for gestational diabetes compared to those on efavirenz-based ART after adjusting for age, BMI, gravidity, CD4, and

Effect: improvement; aOR=0.34; CI: 95% CI=0.12, 0.97